Understanding the natural history of Kaposi Sarcoma
Official title: Natural History Study of Kaposi Sarcoma
Run by National Institutes of Health Clinical Center (CC) · NCT06375122 · Data updated 2026-11-12
This study looks at how Kaposi Sarcoma affects people with weakened immune systems, like those with HIV, by tracking their symptoms and health over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 120 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | May 15, 2024 |
| Main results expected | December 31, 2034 |
| Study ends | December 31, 2036 |
| Registry record updated | November 3, 2026 |
| Trial ID | NCT06375122 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with histologically confirmed Kaposi Sarcoma.
✕Probably not a fit
Patients with active KSHV-associated inflammatory cytokine syndrome, multicentric Castleman disease, or primary effusion lymphoma may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to characterize the natural history of Kaposi Sarcoma (KS), a tumor associated with the Kaposi sarcoma herpesvirus, particularly in individuals with compromised immunity such as those with HIV. Participants aged 18 and older with histologically confirmed KS will undergo physical exams, blood tests, imaging scans, and possibly biopsies to collect data on the disease's presentation, manifestations, and recurrence rates. The study will also assess the impact of KS on the immune system and overall health through longitudinal evaluations and participant-reported outcomes.
Why it matters
Potential benefit: If successful, this study could lead to a better understanding of Kaposi Sarcoma, potentially informing more effective treatments and management strategies for patients.
How similar studies have gone: While the natural history of Kaposi Sarcoma is not fully understood, similar observational studies have provided valuable insights into other cancers, suggesting potential for meaningful findings in this area.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: Participants must have histological KS confirmed by the Laboratory of Pathology (LP), NCI. * KS as assessed by cutaneous or oral KS lesions or other assessable KS disease. * Age \>=18 years. * ECOG performance status \<=4. * Ability of participant to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: * Participants with active KSHV-associated inflammatory cytokine syndrome (KICS), multicentric Castleman disease (MCD), or primary effusion lymphoma (PEL). * Participants with serious and/or uncontrolled severe intercurrent illness, such as opportunistic infections, that in the judgement of the investigator would preclude participation in the study.
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Ramya M Ramaswami, M.D. — National Cancer Institute (NCI)
- Study coordinator: Irene B Ekwede, R.N.
- Email: irene.ekwede@nih.gov
- Phone: (240) 760-6126
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Project SHIELD 2.0: Police Education to Support Public Health in Kentucky
Aimed at police in Kentucky, this program tests whether SHIELD training given to officers, with health workers helping deliver it, can reduce drug-related arrests and steer people who use drugs toward MOUD and other health services.
-
New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV
This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.
-
Bridge to Belonging: A Peer‑Led Program to Reduce Loneliness and Depression in older gay and bisexual men with HIV
This program tests a peer-delivered, manualized approach to help men aged 50+ with HIV connect to LGBTQ+-affirming elder services to see if it reduces loneliness and depressive symptoms.
-
HIV vaccine test in healthy adults using CH505 nanoparticles and mRNA boosters
This early-stage study will test the safety and immune responses of CH505 vaccine regimens in healthy adults to see if they can trigger HIV-specific immune protection.
-
Stigma-reducing program to help women who use drugs stay in HIV care
This test checks whether a stigma-reduction program helps women living with HIV who use drugs stay engaged in HIV care in Ukraine.
-
Platelets and HIV Reservoirs: A look at how platelets might harbor HIV in people living with HIV
This observational study tests whether HIV can be found inside platelets in adults with suppressed HIV on therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.